Introduction to Regulatory Approvals & Agencies
This unit decrypts the specific legal applications required by pharmaceutical companies to move a drug through development into the commercial market. You will learn the exact sequence and purpose of the IND, NDA, and ANDA filings. Furthermore, it provides an organizational overview of the supreme government agencies that dictate the rules of the global pharmaceutical trade, including the USFDA, EMA, and India’s CDSCO.
Syllabus & Topics
- 1Investigational New Drug (IND) Application: The critical legal application filed by the innovator to the FDA asking for permission to BEGIN testing an unapproved drug in HUMAN subjects (Clinical Trials). Contents: Extensive pre-clinical animal toxicity data, manufacturing chemistry details, and detailed clinical protocols (how they plan to safely test humans). Timeline: The FDA has strictly 30 days to review the IND. If the FDA does not issue a ‘Clinical Hold’ within 30 days, the sponsor can automatically begin Phase 1 trials.
- 2New Drug Application (NDA): The ultimate, colossal application filed by the innovator asking for permission to SELL the new drug to the public. Filed AFTER the successful completion of Phase 3 clinical trials. Contents: Every single piece of data generated over 15 years—animal studies, massive human clinical efficacy/safety data, exact manufacturing processes, and proposed product labeling. Timeline: Standard review takes ~10-12 months. Priority review for life-saving drugs takes ~6 months.
- 3Abbreviated New Drug Application (ANDA): The application filed by a generic manufacturer to market a generic copy of an already approved innovator drug. ‘Abbreviated’ signifies that extensive, expensive pre-clinical animal data and massive Phase 3 human clinical efficacy data are NOT REQUIRED. Contents: The sponsor must only scientifically prove Bioequivalence, ensure identical quality chemistry/manufacturing (CMC), and match the innovator’s labeling. Approval allows the generic to compete on price post-patent expiry.
- 4Changes to an Approved Application (Supplements): Once an NDA/ANDA is approved, a company cannot arbitrarily change the manufacturing process. Supplemental New Drug Application (sNDA/sANDA): Filed if the company wants to make significant changes. E.g., changing the manufacturing facility, changing synthesis ingredients, adding a new pediatric dose, or updating the label to include a new warning. Major changes require ‘Prior Approval’ before implementation.
- 5Global Regulatory Agencies – Overview: Different nations have sovereign agencies governing drug safety, though they increasingly harmonize standards. Organization Structure & Applications: (1) India: CDSCO (Central Drugs Standard Control Organisation), headed by the DCGI. (2) United States: USFDA (Food and Drug Administration) – The global gold standard. (3) European Union: EMA (European Medicines Agency) – Utilizes Centralized/Decentralized procedures for 27 member states. (4) Australia: TGA (Therapeutic Goods Administration). (5) Japan: PMDA (Pharmaceuticals and Medical Devices Agency). (6) Canada: Health Canada.
Learning Objectives
Exam Prep Questions
Q1. Why does the FDA only have 30 days to review an IND?
The 30-day window for an Investigational New Drug (IND) is a strict regulatory mechanism to prevent bureaucratic delays from stalling crucial medical research. The primary focus of the IND review is purely “Safety” (ensuring the human volunteers won’t be harmed in Phase 1), not efficacy. If the FDA reviewers find a safety flaw, they place a “Clinical Hold”. If not, the silence is counted as tacit approval to proceed, accelerating the discovery timeline.
Q2. Can an innovator company file an NDA solely based on animal data?
Absolutely not. Pre-clinical animal data ONLY allows a company to file an IND to start human testing. The entire purpose of a New Drug Application (NDA) is to prove the drug is safe and effective in humans. An NDA must contain massive volumes of data from successful Phase 1, Phase 2, and Phase 3 HUMAN clinical trials before the FDA will allow the drug to be commercially sold.
Q3. If a generic company wants to add a strawberry flavor to their generic syrup, do they just do it?
No. The pharmaceutical industry is strictly change-controlled. Even a small change like altering an inactive flavoring agent in an already approved generic drug requires submitting a Supplemental ANDA (sANDA) to the FDA. The company must prove that adding the strawberry flavor does not alter the stability of the active ingredient or negatively impact the drug’s critical bioequivalence before they can legally sell the new flavored version.